Epidemiology of invasive candidiasis: a persistent public health problem.
PDF (319K)
Journal: 2007/March - Clinical Microbiology Reviews
ISSN: 0893-8512
Abstract:
Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in the United States. We examined data from the National Center for Health Statistics and reviewed recent literature in order to update the epidemiology of IC. IC-associated mortality has remained stable, at approximately 0.4 deaths per 100,000 population, since 1997, while mortality associated with invasive aspergillosis has continued to decline. Candida albicans remains the predominant cause of IC, accounting for over half of all cases, but Candida glabrata has emerged as the second most common cause of IC in the United States, and several less common Candida species may be emerging, some of which can exhibit resistance to triazoles and/or amphotericin B. Crude and attributable rates of mortality due to IC remain unacceptably high and unchanged for the past 2 decades. Nonpharmacologic preventive strategies should be emphasized, including hand hygiene; appropriate use, placement, and care of central venous catheters; and prudent use of antimicrobial therapy. Given that delays in appropriate antifungal therapy are associated with increased mortality, improved use of early empirical, preemptive, and prophylactic therapies should also help reduce IC-associated mortality. Several studies have now identified important variables that can be used to predict risk of IC and to help guide preventive strategies such as antifungal prophylaxis and early empirical therapy. However, improved non-culture-based diagnostics are needed to expand the potential for preemptive (or early directed) therapy. Further research to improve diagnostic, preventive, and therapeutic strategies is necessary to reduce the considerable morbidity and mortality associated with IC.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(929)
References
(317)
Diseases
(1)
Drugs
(1)
Chemicals
(1)
Organisms
(2)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Clin Microbiol Rev 20(1): 133-163
PMID: 17223626

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

Departments of Pathology, Medicine, College of Medicine, Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 522423
Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 356-8615. Fax: (319) 356-4916. E-mail: ude.awoiu@rellafp-leahcim.
Copyright © 2007, American Society for Microbiology

Abstract

Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in the United States. We examined data from the National Center for Health Statistics and reviewed recent literature in order to update the epidemiology of IC. IC-associated mortality has remained stable, at approximately 0.4 deaths per 100,000 population, since 1997, while mortality associated with invasive aspergillosis has continued to decline. Candida albicans remains the predominant cause of IC, accounting for over half of all cases, but Candida glabrata has emerged as the second most common cause of IC in the United States, and several less common Candida species may be emerging, some of which can exhibit resistance to triazoles and/or amphotericin B. Crude and attributable rates of mortality due to IC remain unacceptably high and unchanged for the past 2 decades. Nonpharmacologic preventive strategies should be emphasized, including hand hygiene; appropriate use, placement, and care of central venous catheters; and prudent use of antimicrobial therapy. Given that delays in appropriate antifungal therapy are associated with increased mortality, improved use of early empirical, preemptive, and prophylactic therapies should also help reduce IC-associated mortality. Several studies have now identified important variables that can be used to predict risk of IC and to help guide preventive strategies such as antifungal prophylaxis and early empirical therapy. However, improved non-culture-based diagnostics are needed to expand the potential for preemptive (or early directed) therapy. Further research to improve diagnostic, preventive, and therapeutic strategies is necessary to reduce the considerable morbidity and mortality associated with IC.

Abstract

Acknowledgments

This work was supported in part by grants from Pfizer, Schering-Plough, and Astellas Pharma US, Inc.

Linda Elliott provided excellent assistance in the preparation of the manuscript. Stephen J. Gentles was very helpful in compiling some of the data presented in the tables and figures.

Acknowledgments

REFERENCES

REFERENCES

References

  • 1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis.24:1122-1128. [[PubMed]
  • 2. Ables, A. Z., N. A. Blumer, G. T. Valainis, M. T. Godenick, D. K. Kajdasz, and Y. Y. Palesch. 2000. Fluconazole prophylaxis of severe Candida infections in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect. Dis. Clin. Pract.9:169-175. [PubMed]
  • 3. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation80:868-871. [[PubMed]
  • 4. Alexander, B. D., and M. A. Pfaller. 2006. Contemporary tools for the diagnosis and management of invasive mycoses. Clin. Infect. Dis.43:S15-S27. [PubMed]
  • 5. Almirante, B., D. Rodriguez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, P. Sabolls, S. K. Fridkin, J. Morgan, J. L. Rodriguez-Tudela, D. W. Warnock, A. Pahissa, and the Barcelona Candidemia Project Study Group. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol.43:1829-1835.
  • 6. Almirante, B., D. Rodriguez, M. Cuenca-Estrella, M. Almela, F. Sanchez, J. Ayata, C. Alonso-Tarres, J. L. Rodriguez-Tudela, A. Pahissa, and the Barcelona Candidemia Project Study Group. 2006. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol.44:1681-1685.
  • 7. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother.47:1179-1186.
  • 8. Andes, D., K. Marchill, J. Lawther, A. Bryskier, T. Stamstad, and R. Conklin. 2003. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother.47:1187-1192.
  • 9. Antoniadou, A., H. A. Torres, R. E. Lewis, J. Thornby, G. P. Bodey, J. P. Tarrand, X. Y. Han, K. V. Rolston, A. Safdar, I. I. Raad, and D. P. Kontoyiannis. 2003. Candidemia in a tertiary care center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine82:309-321. [[PubMed]
  • 10. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgen, J. C. Schonheyden, and M. Tvede. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and number of isolates with reduced azole susceptibility. J. Clin. Microbiol.43:4434-4440.
  • 11. Asmundsdottir, L. R., H. Erlendsdottir, and M. Gottfredsson. 2002. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol.40:3489-3492.
  • 12. Bachman, S. P., T. F. Patterson, and J. Lopez-Ribot. 2002. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resisance. J. Clin. Microbiol.40:2228-2230.
  • 13. Baddley, J. W., A. M. Smith, S. A. Moser, and P. G. Pappas. 2001. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital. Diagn. Microbiol. Infect. Dis.39:199-201. [[PubMed]
  • 14. Baddley, J. W., P. Pappas, A. C. Smith, and S. A. Moser. 2003. Epidemiology of Aspergillus terreus at a university hospital. J. Clin. Microbiol.41:5525-5529.
  • 15. Baddley, J. W., M. Patel, M. Jones, G. Cloud, A. C. Smith, and S. A. Moser. 2004. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn. Microbiol. Infect. Dis.50:119-124. [[PubMed]
  • 16. Baily, G. G., C. B. Moore, S. M. Essayag, S. de Wit, J. P. Burnie, and D. W. Denning. 1997. Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Clin. Infect. Dis.25:161-162. [[PubMed]
  • 17. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother.50:2058-2063.
  • 18. Baran, J., Jr., B. Buckatira, and R. Khatib. 2001. Candidemia before and during the fluconazole era: prevalence, types of species and approach to treatment in a tertiary care community hospital. Scand. J. Infect. Dis.33:137-139. [[PubMed]
  • 19. Barchiesi, F., D. Arzeni, F. Caselli, and G. Scalise. 2000. Primary resistance to flucytosine among clinical isolates of Candida spp. J. Antimicrob. Chemother.45:401-412. [[PubMed]
  • 20. Barchiesi, F., E. Spreghini, S. Tomassetti, A. D. Vittoria, D. Arzeni, E. Manso, and G. Scalise. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother.50:2719-2727.
  • 21. Bartizal, K., and F. C. Odds. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother.47:2100-2107.
  • 22. Blignaut, E., C. Pujol, S. Lockhart, S. Joly, and D. R. Soll. 2002. Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa. J. Clin. Microbiol.40:826-836.
  • 23. Blignaut, E., J. Molepo, C. Pujol, D. R. Soll, and M. A. Pfaller. 2005. Clade-related amphotericin B resistance among South African Candida albicans isolates. Diagn. Microbiol. Infect. Dis.53:29-31. [[PubMed]
  • 24. Blot, S. I., K. H. Vandewoude, E. A. Hoste, and F. A. Colardyn. 2002. Effects of nosocomial candidemia on outcomes of critically ill patients. Am. J. Med.113:480-485. [[PubMed]
  • 25. Blot, S. I., and K. H. Vandewoude. 2003. Estimating attributable mortality of candidemia: clinical judgment vs. matched cohort studies. Eur. J. Clin. Microbiol. Infect. Dis.22:132-133. [[PubMed]
  • 26. Blumberg, H. M., W. R. Jarvis, J. M. Soucie, J. E. Edwards, J. E. Patterson, M. A. Pfaller, M. S. Rangel-Frausto, M. G. Rinaldi, L. Saiman, R. T. Wiblin, R. P. Wenzel, and the NEMIS Study Group. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin. Infect. Dis.33:177-186. [[PubMed]
  • 27. Borst, A., M. T. Raimer, D. W. Warnock, C. J. Morrison, and B. A. Arthington-Skaggs. 2005. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob. Agents Chemother.49:783-787.
  • 28. Boyce, J. M., and D. Pittet. 2002. Guideline for hand hygiene in health-care settings. Morb. Mortal. Wkly. Rep.51(RR-16):1-45. [[PubMed]
  • 29. Branchini, M. L., M. A. Pfaller, J. Rhine-Chalberg, T. Frempong, and H. D. Isenberg. 1994. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J. Clin. Microbiol.32:452-456.
  • 30. Calandra, T., and OMarchetti. 2002. Antifungal prophylaxis for intensive care unit patients: let's fine tune it. Intensive Care Med.28:1698-1700. [[PubMed][Google Scholar]
  • 31. Canton, E., J. Peman, M. Gobernado, A. Viudes, and A. Espinel-Ingroff. 2004. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother.48:2477-2482.
  • 32. Chandrasekar, P. H., and J. D. Sobel. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis.42:1171-1178. [[PubMed]
  • 33. Charles, PE. 2006. Multifocal Candida species colonization as a trigger for early antifungal therapy in critically ill patients: what about other risk factors for fungal infection? Crit. Care Med.34:913-914. [[PubMed][Google Scholar]
  • 34. Charlier, C., E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary. 2006. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother.57:384-410. [[PubMed]
  • 35. Chen, A., and J. D. Sobel. 2005. Emerging azole antifungals. Expert Opin. Emerg. Drugs10:21-33. [[PubMed]
  • 36. Chen, Y. C., S. C. Chang, K. T. Luh, and W. C. Hsieh. 2003. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother.52:71-77. [[PubMed]
  • 37. Cheng, M. F., K. W. Yu, R. B. Tang, Y. H. Fan, Y. L. Yang, K. S. Hsieh, M. Ho, and H. J. Lo. 2004. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis.48:33-37. [[PubMed]
  • 38. Chryssanthous, E. 2001. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J. Clin. Microbiol.39:4181-4183.
  • 39. Chu, J. H., C. Feudtner, K. Heydon, T. J. Walsh, and T. E. Zaoutis. 2006. Hospitalizations for endemic mycoses: a population-based national study. Clin. Infect. Dis.42:822-825. [[PubMed]
  • 40. Clancy, C. J., and M. H. Nguyen. 1999. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob. Agents Chemother.43:1289-1290.
  • 41. Clark, T. A., S. A. Slavinski, J. Morgan, T. Lott, B. A. Arthington-Skaggs, M. E. Brandt, R. M. Webb, M. Carrier, R. H. Flowers, S. K. Fridken, and R. A. Hajjeh. 2004. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J. Clin. Microbiol.42:4468-4472.
  • 42. Colombo, A. L., M. Nucci, R. Salomao, M. L. M. Branchini, R. Richtmann A. Derossi, and S. B. Wey. 1999. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn. Microbiol. Infect. Dis.34:281-286. [[PubMed]
  • 43. Colombo, A. L., A. S. A. Melo, R. F. C. Rosas, R. Salomao, M. Briones, R. J. Hollis, S. A. Messer, and M. A. Pfaller. 2003. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn. Microbiol. Infect. Dis.46:253-257. [[PubMed]
  • 44. Colombo, A. L., J. Perfect, M. DiNubile, K. Bartizal, M. Motyl, P. Hicks, R. Lupinacci, C. Sable, and N. Kartsonis. 2003. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis.22:470-474. [[PubMed]
  • 45. Coopersmith, C. M., T. L. Rebmann, J. E. Zack, M. R. Ward, R. M. Corcoran, M. E. Schallom, C. S. Sona, T. G. Buchman, W. A. Boyle, L. B. Polish, and V. J. Fraser. 2002. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care units. Crit. Care Med.30:59-64. [[PubMed]
  • 46. Cordonnier, C., P. Ribaud, R. Herbrecht, N. Milpied, D. Valteaa-Couanet, C. Morgan, and A. Wade. 2006. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin. Infect. Dis.42:955-963. [[PubMed]
  • 47. Cornet, M., L. Fleury, C. Maslo, J. F. Bernard, G. Brucker, and the Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hopitaux de Paris. 2002. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J. Hosp. Infect.51:288-296. [[PubMed]
  • 48. Cruciani, M., F. de Lalla, and C. Mengoli. 2005. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med.31:1479-1487. [[PubMed]
  • 49. Cuenca-Estrella, M., T. M. Diaz-Guerra, E. Mellado, and J. L. Rodriguez-Tudela. 2001. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur. J. Clin. Microbiol. Infect. Dis.20:276-279. [[PubMed]
  • 50. Cuenca-Estrella, M., L. Rodero, G. Garcia-Effron, and J. L. Rodriguez-Tudela. 2002. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J. Antimicrob. Chemother.49:981-987. [[PubMed]
  • 51. Cuenca-Estrella, M., D. Rodriguez, B. Almirante, J. Morgan, A. M. Planis, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, M. Salvado, D. W. Warnock, A. Pahissa, and J. L. Rodriguez-Tudela. 2005. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother.55:194-199. [[PubMed]
  • 52. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother.50:917-921.
  • 53. D'Antonio, D., B. Violante, A. Mazzoni, T. Bonfini, M. A. Capuani, F. D'Aloia, A. Iacone, F. Schioppa, and F. Romano. 1998. A nosocomial cluster of Candida inconspicua infections in patients with hematological malignancies. J. Clin. Microbiol.36:792-795.
  • 54. Dasbach, E. J., G. M. Davies, and S. M. Teutsch. 2000. Burden of aspergillosis-related hospitalizations in the United States. Clin. Infect. Dis.31:1524-1528. [[PubMed]
  • 55. Davies, H. D., A. McGeer, B. Schwartz, K. Green, D. Can, A. E. Simor, and D. E. Low for the Ontario Group A Streptococcal Study Group. 1996. Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med.335:547-554. [[PubMed]
  • 56. De Repentigny, L., M. Phaneuf, and L. G. Mathieu. 1992. Gastrointestinal colonization and systemic dissemination by C. albicans and C. tropicalis in intact and immunocompromised mice. Infect. Immun.60:4907-4914.
  • 57. Deresinski, C. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis.36:1445-1457. [[PubMed]
  • 58. Dick, J. D., R. P. Rosengard, W. G. Merz, R. K. Stuart, G. M. Hutchins, and R. Saral. 1985. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann. Intern. Med.102:67-68. [[PubMed]
  • 59. Diekema, D. J., S. A. Messer, R. J. Hollis, R. P. Wenzel, and M. A. Pfaller. 1997. An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn. Microbiol. Infect. Dis.29:147-153. [[PubMed]
  • 60. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J. Clin. Microbiol.40:1298-1302.
  • 61. Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol.41:3623-3626.
  • 62. Diekema, D. J., and M. A. Pfaller. 2004. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect. Control Hosp. Epidemiol.25:624-626. [[PubMed]
  • 63. Dignani, M. C., J. S. Solomkin, and E. J. Anaissie. 2003. Candida, p. 195-239. In E. J. Anaissie, M. R. McGinnis, and M. A. Pfaller (ed.), Clinical mycology. Churchill Livingstone, New York, NY.
  • 64. Dodds Ashley, E. S., R. Lewis, J. S. Lewis, C. Martin, and D. Andes. 2006. Pharmacology of systemic antifungal agents. Clin. Infect. Dis.43(Suppl. 1):S28-S39. [PubMed]
  • 65. Dodgson, A. R., K. J. Dodgson, C. Pujol, M. A. Pfaller, and D. R. Soll. 2004. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother.48:2223-2227.
  • 66. Dodgson, K. J., A. R. Dodgson, C. Pujol, S. A. Messer, D. R. Soll, and M. A. Pfaller. 2005. Caspofungin-resistant C. glabrata. Clin. Microbiol. Infect.11(Suppl. 2):364. [PubMed]
  • 67. Doebbeling, B. N., G. L. Stanley, C. T. Sheetz, M. A. Pfaller, and R. P. Wenzel. 1992. Comparative efficacy of alternative hand washing agents in reducing nosocomial infections in intensive care units. N. Engl. J. Med.327:88-93. [[PubMed]
  • 68. Dube, M. P., P. N. Heseltine, M. G. Rinaldi, S. Evans, and B. Zawacki. 1994. Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin. Infect. Dis.18:77-82. [[PubMed]
  • 69. Dupont, H., A. Bourichon, C. Paugam-Burtz, J. Mantz, and J. M. Desmounts. 2003. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit. Care Med.31:752-757. [[PubMed]
  • 70. Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis.29:239-244. [[PubMed]
  • 71. Edwards, J. E., G. P. Bodey, R. A. Bowden, T. Buchner, B. E. DePauw, S. G. Filler, M. A. Ghannoum, M. Glauser, R. Herbrecht, C. A. Kauffman, S. Kohno, P. Mortino, F. Meanier, T. Mori, M. A. Pfaller, J. H. Rex, T. R. Rogers, R. H Rubin, J. Solomkin, C. Viscoli, T. J. Walsh, and M. White. 1997. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis.25:43:59. [[PubMed]
  • 72. Eggimann, P., P. Francioli, J. Bille, R. Schneider, M. M. Wu, G. Chapuis, R. Chiolero, A. Pannatier, J. Schilling, S. Geroulanos, M. P. Glausen, and T. Calandra. 1999. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med.27:1066-1072. [[PubMed]
  • 73. Eggimann, P., J. Garbino, and D. Pittet. 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis.3:685-702. [[PubMed]
  • 74. Eggimann, P., T. Calandra, U. Fluckiger, J. Bille, J. Garbino, M. P. Glauser, O. Marchetti, C. Ruef, M. Tauber, D. Pittet, and the Fungal Infection Network of Switzerland. 2005. Invasive candidiasis: comparison of management choices by infectious diseases and critical care specialists. Intensive Care Med.31:1514-1517. [[PubMed]
  • 75. Ernst, E. J., M. E. Klepser, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis.33:75-80. [[PubMed]
  • 76. Ernst, E. J., M. E. Klepser, and M. A. Pfaller. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother.44:1108-1111.
  • 77. Farley, M. M., R. C. Harvey, T. Stull, J. D. Smith, A. Shuchat, J. D. Wenger, and D. S. Stephens. 1993. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N. Engl. J. Med.328:1807-1811. [[PubMed]
  • 78. Favel, A., A. Michel-Nguyen, A. Datry, S. Challier, F. Leclerc, C. Chastin, K. Fallague, and P. Regli. 2004. Susceptibility of clinical isolates of C. lusitaniae to five systemic antifungal agents. J. Antimicrob. Chemother.53:526-529. [[PubMed]
  • 79. Fidel, P. L., Jr., J. A. Vazquez, and J. D. Sobel. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev.12:80-96.
  • 80. Fisher-Hoch, S. P., and L. Hutwagner. 1995. Opportunistic candidiasis: an epidemic of the 1980s. Clin. Infect. Dis.21:897-904. [[PubMed]
  • 81. Frances, P., and T. J. Walsh. 1992. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis.15:1003-1018. [[PubMed]
  • 82. Fridkin, SK. 2005. Candidemia is costly—plain and simple. Clin. Infect. Dis.41:1240-1241. [[PubMed][Google Scholar]
  • 83. Fridkin, SK. 2005. The changing face of fungal infections in health care settings. Clin. Infect. Dis.41:1455-1460. [[PubMed][Google Scholar]
  • 84. Fukuoka, T., D. A. Johnston, C. A. Winslow, M. J. de Groot, C. Burt, C. A. Hitchock, and S. G. Filler. 2003. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob. Agents Chemother.47:1213-1219.
  • 85. Garbino, J., D. P. Lew, J. A. Romand, S. Hugnonnet, R. Auckenthaler, and D. Pittet. 2002. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive-decontamination. Intensive Care Med.28:1708-1717. [[PubMed]
  • 86. Garrouste-Orgeas, M., J. F. Timsit, M. Tafflet, V. Misset, J. R. Zahar, L. Soufir, T. Lazard, S. Jamali, B. Mourvillier, Y. Cohen, A. DeLassence, E. Azoulay, C. Cheval, A. Descrops-Declere, C. Adrie, M. A. Costade Beuregard, and J. Corlet. 2006. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infectons: a reappraisal. Clin. Infect. Dis.42:1118-1126. [[PubMed]
  • 87. Gauzit, R., Y. Cohen, H. Dupont, C. Hennequin, P. Montravers, J. F. Timsit, B. Veber, E. Chevalier, P. Blin, and B. Palestro. 2003. Infections by Candida sp. in intensive care. Survey of French practices. Presse Med.32:440-449. [[PubMed]
  • 88. Gavalda, J., O. Len, R. San Juan, J. M. Aguado, J. Fortun, C. Lumbreras, A. Moreno, P. Munoz, M. Blanes, A. Ramos, G. Rufi, M. Gurgui, J. Torri-Cisneros, M. Montegjo, M. Cuenca-Estrella, J. L. Rodriguez-Tudela, and A. Pahissa. 2005. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin. Infect. Dis.41:52-59. [[PubMed]
  • 89. Ghannoum, M., and MD'Angelo. 2005. Anidulafungin: a potent antifungal that targets Candida and Aspergillus. Infect. Dis. Clin. Pract.13:165-178. [PubMed][Google Scholar]
  • 90. Gibbs, W. J., R. H. Drew, and J. R. Perfect. 2005. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev. Anti-Infect. Ther.3:167-181. [[PubMed]
  • 91. Glasmacher, A., O. A. Cornely, K. Orlopps, S. Reuter, S. Blaschke, M. Eichel, G. Silling, B. Simons, G. Egerer, M. Siemann, M. Florek, R. Schnitzler, P. Ebeling, J. Ritter, H. Reinel, P. Schutt, H. Fischer, C. Hahn, and G. Just-Nuebling. 2006. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J. Antimicrob. Chemother.57:127-134. [[PubMed]
  • 92. Graybill, JR. 2005. Voriconazole for candidosis: an important addition. Lancet366:1413-1414. [[PubMed][Google Scholar]
  • 93. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis.37:1172-1177. [[PubMed]
  • 94. Gumbo, T., C. M. Isada, G. Hall, M. T. Karafa, and S. M. Gordon. 1999. Candida glabrata fungemia: clinical features of 139 patients. Medicine (Baltimore)78:220-227. [[PubMed]
  • 95. Hadley, S., J. A. Martinez, L. McDermott, B. Rapino, and D. R. Snydman. 2002. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J. Antimicrob. Chemother.49:415-419. [[PubMed]
  • 96. Hajjeh, R. A., A. N. Sofair, I. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. A. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol.42:1519-1527.
  • 97. Harbarth, S., K. Kerriere, S. Hugonette, B. Ricou, P. Sutter, and D. Pittet. 2002. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch. Surg.137:1353-1359. [[PubMed]
  • 98. Hawkins, J. L., and L. M. Baddour. 2003. Candida lusitaniae infections in the era of fluconazole availability. Clin. Infect. Dis.36:e14-e18. [[PubMed]
  • 99. Hay, RJ. 2003. Cutaneous and subcutaneous mycoses, p. 456-473. In E. J. Anaissie, M. R. McGinnis, and M. A. Pfaller (ed.), Clinical mycology. Churchill Livingstone, New York, NY.[Google Scholar]
  • 100. Hazen, KC. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev.8:462-478. [Google Scholar]
  • 101. Hazen, K. C., and S. A. Howell. 2003. Candida, Cryptococcus, and other yeasts of medical importance, p. 1693-1711. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, DC.
  • 102. Hazen, K. C., E. J. Baron, A. L. Colombo, C. Girmenia, A. Sanchez-Souza, A. del Palacio, C. de Bedout, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2003. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J. Clin. Microbiol.41:5623-5632.
  • 103. Hedderwick, S. A., J. Y. Wan, S. F. Bradley, J. A. Sangeorzan, M. S. Terpening, and C. A. Kauffman. 1998. Risk factors for colonization with yeast species in a Veterans Affairs long-term care facility. J. Am. Geriatr. Soc.46:849-853. [[PubMed]
  • 104. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Green, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribuad, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, C. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347:408-415. [[PubMed]
  • 105. Hernandez, S., G. M. Gonzalez, D. I. McCarthy, A. L. Colombo, L. K. Najvar, R. Bocanegera, and J. R. Graybill. 2004. Alternatives to amphotericin B for Candida rugosa infection. J. Antimicrob. Chemother.54:477-480. [[PubMed]
  • 106. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother.48:1382-1383.
  • 107. Ho, K. M., J. Lipman, G. J. Dobb, and S. A. R. Webb. 2005. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit. Care9:R710-R717.
  • 108. Hoban, D. J., G. G. Zhanel, and J. A. Karlowski. 1999. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother.43:1463-1464.
  • 109. Hobson, RP. 2003. The global epidemiology of invasive Candida infections—is the tide turning? J. Hosp. Infect.55:159-168. [[PubMed][Google Scholar]
  • 110. Horvath, L. L., B. J. George, C. K. Murray, L. S. Harrison, and D. R. Hospenthal. 2004. Direct comparison of the BACTEC 9320 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J. Clin. Microbiol.42:115-118.
  • 111. Hseuh, P. R., L. J. Teng, P. C. Yang, S. W. Ho, and K. T. Luh. 2002. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb. Drug Resist.8:311-319. [[PubMed]
  • 112. Hseuh, P. R., Y. J. Lau, Y. C. Chuang, J. H. Wan, W. K. Huang, J. M. Syr, J. J. Yan, K. W. Yu, J. J. Wu, W. C. Ko, Y. C. Yang, Y. C. Liu, L. J. Teng, C. Y. Lin, and K. T. Luh. 2005. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother.49:512-517.
  • 113. Ibrahim, E. H., G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest118:146-155. [[PubMed]
  • 114. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis.20:342-347. [[PubMed]
  • 115. Jacobs, S., D. A. Price Evans, M. Tariq, and N. F. al Omarl. 2003. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit. Care Med.31:1938-1946. [[PubMed]
  • 116. Johnson, L. B., and C. A. Kauffman. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36:630-637. [[PubMed]
  • 117. Kao, A. S., M. E. Brandt, W. R. Pruitt, L. A. Conn, B. A. Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis.29:1164-1170. [[PubMed]
  • 118. Kartsonis, N., J. Killar, L. Mixson, C. M. Hoe, C. Sable, K. Bartizal, and M. Motyl. 2005. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother.49:3616-3623.
  • 119. Katiyar, S., M. Pfaller, and E. Edlind. 2006. Characterization of Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother.50:2892-2894.
  • 120. Kauffman, CA. 2001. Fungal infections in older adults. Clin. Infect. Dis.33:550-555. [[PubMed][Google Scholar]
  • 121. Kaufman, D., R. Boyle, K. C. Hazen, J. T. Patrie, M. Robinson, and L. G. Donowitz. 2001. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med.345:1660-1666. [[PubMed]
  • 122. Kontoyiannis, D. P., I. Vaziri, H. A. Hanna, M. Boktour, J. Thornby, R. Hachem, G. P. Bodey, and I. I. Raad. 2001. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin. Infect. Dis.33:1676-1681. [[PubMed]
  • 123. Krause, D. S., J. Reinhardt, J. A. Vazquez, A. Reboli, B. P. Goldstein, M. Wible, and T. Henkel. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother.48:2021-2024.
  • 124. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis.42:938-944. [[PubMed]
  • 125. Kuhn, D. M., J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect. Immun.70:878-888.
  • 126. Kuhn, D. M., P. K. Mukherjee, T. A. Clark, C. Pujol, J. Chandra, R. A. Hajjeh, D. W. Warnock, D. R. Soll, and M. A. Ghannoum. 2004. Candida parapsilosis characterization in an outbreak setting. Emerg. Infect. Dis.10:1074-1081.
  • 127. Kullberg, B. J., J. D. Sobel, M. Rhunke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. P. Church, J. M. Brown, H. T. Schlamm, I. T. Oborska, F. Hilton, and M. R. Hodges. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet366:1435-1442. [[PubMed]
  • 128. Kurtz, M. B., G. Abruzzo, A. Flattery, K. Bartizal, J. A. Morrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun.64:3244-3251.
  • 129. Laupland, K. B., D. B. Gregson, D. L. Church, T. Ross, and S. Elsayed. 2005. Invasive Candida species infections: a 5 year population-based assessment. J. Antimicrob. Chemother.56:532-537. [[PubMed]
  • 130. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother.57:705-708. [[PubMed]
  • 131. Law, D., C. B. Moore, and D. W. Denning. 1997. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J. Antimicrob. Chemother.40:109-112. [[PubMed]
  • 132. Leon, C., S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, F. Alvarez-Lerma, J. Garnacho-Montero, and M. A. Leon. 2006. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit. Care Med.34:730-737. [[PubMed]
  • 133. Levin, A. S., S. F. Costa, N. S. Mussi, M. Basso, S. I. Sinto, C. Machado, C. Geiger, M. C. Villares, A. Z. Schreiber, A. A. Barone, and M. L. Branchini. 1998. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn. Microbiol. Infect. Dis.30:243-249. [[PubMed]
  • 134. Levy, I., L. G. Rubin, S. Vasishtha, V. Tucci, and S. K. Sood. 1998. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin. Infect. Dis.26:1086-1088. [[PubMed]
  • 135. Lin, M. Y., Y. Carmeli, J. Zumsteg, E. L. Flores, J. Tolentino, P. Sreeramoju, and S. G. Weber. 2005. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob. Agents Chemother.49:4555-4560.
  • 136. Lin, S., J. Schranz, and S. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis.32:358-366. [[PubMed]
  • 137. Lipsett, PA. 2004. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin. Infect. Dis.39:S193-S199. [[PubMed][Google Scholar]
  • 138. Liu, K. H., C. J. Wu, C. H. Chou, H. C. Lee, N. Y. Lee, S. T. Hung, and W. C. Ko. 2004. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J. Clin. Microbiol.42:5950-5953.
  • 139. Lockhart, S. R., S. Joly, K. Vargas, J. Swails-Wenger, L. Enger, and D. R. Soll. 1999. Natural defenses against Candida colonization break down in the oral cavities of the elderly. J. Dent. Res.78:857-868. [[PubMed]
  • 140. Lortholary, O., A. Charlemagne, F. Bastides, P. Chevalier, A. Datry, M. F. Gonzalves, G. Michel, P. Tilleul, B. Veber, and R. Herbrecht. 2004. A multicenter pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J. Antimicrob. Chemother.54:456-464. [[PubMed]
  • 141. Louie, A., M. Deziel, W. Liu, M. F. Drusano, T. Gumbo, and G. L. Drusano. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother.49:5058-5068.
  • 142. Lupetti, A., A. Tavanti, P. Davini, E. Ghelardi, V. Corsini, I. Meusi, A. Boldrini, M. Campa, and S. Senesi. 2002. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J. Clin. Microbiol.40:2363-2369.
  • 143. Luzzati, R., G. Amalfitano, L. Lazzarini, F. Soldori, S. Bellino, M. Solbiatic, M. C. Danzi, S. Vento, G. Todeschini, C. Vivenza, and E. Concia. 2000. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis.19:602-607. [[PubMed]
  • 144. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol.44:529-535.
  • 145. Majoros, L., G. Karso, A. Belak, A. Maraz, L. Asztalos, E. Csanky, Z. Barta, and B. Szado. 2003. Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures. J. Clin. Microbiol.41:5250-5253.
  • 146. Majoros, L., G. Kardos, P. Feiszt, and B. Szabo. 2005. Efficacy of amphotericin B and flucytosine against fluconazole-resistant Candida inconspicua clinical isolates. J. Antimicrob. Chemother.56:253-254. [[PubMed]
  • 147. Majoros, L., G. Karso, B. Szabo, M. Kovacs, and A. Maraz. 2005. Fluconazole susceptibility testing of Candida inconspicua clinical isolates: comparison of four methods. J. Antimicrob. Chemother.55:275-276. [[PubMed]
  • 148. Majoros, L., G. Karso, B. Szabo, and M. Sipiczki. 2005. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration. Antimicrob. Agents Chemother.49:3486-3488.
  • 149. Malani, A., J. Hmoud, L. Chiu, P. L. Carver, A. Bielaczyc, and C. A. Kauffman. 2005. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis.41:975-981. [[PubMed]
  • 150. Malani, P. N., S. F. Bradley, R. S. Little, and C. A. Kauffman. 2001. Trends in species causing fungemia in a tertiary care medical centre over 12 years. Mycoses44:446-449. [[PubMed]
  • 151. Marchetti, O., J. Bille, U. Fluckinger, P. Eggimann, C. Ruef, J. Garbino, T. Calandra, M. P. Glauser, M. G. Tauber, and D. Pittet. 2004. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis.38:311-320. [[PubMed]
  • 152. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis.181:309-316. [[PubMed]
  • 153. Marr, K. A., R. A. Carter, F. Crippa, A. Wold, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34:909-917. [[PubMed]
  • 154. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med.348:1546-1554. [[PubMed]
  • 155. Masala, L., R. Luzzati, L. Maccacaro, L. Antozzi, E. Concia, and R. Fontana. 2003. Nosocomial cluster of Candida guilliermondii fungemia in surgical patients. Eur. J. Clin. Microbiol. Infect. Dis.22:686-688. [[PubMed]
  • 156. Maschmeyer, G., and AGlasmacher. 2005. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses48:227-234. [[PubMed][Google Scholar]
  • 157. McClenny, N. B., H. Fei, E. J. Baron, A. C. Gales, A. Houston, R. J. Hollis, and M. A. Pfaller. 2002. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob. Agents Chemother.46:1325-1328.
  • 158. McNeil, M. M., S. L. Nash, R. A. Hajjeh, M. A. Phelan, L. A. Conn, B. D. Plikaytis, and D. W. Warnock. 2001. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis.33:641-647. [[PubMed]
  • 159. Medoff, G., and G. S. Kobayashi. 1980. Strategies in the treatment of systemic fungal infections. N. Engl. J. Med.302:145-155. [[PubMed]
  • 160. Merz, W. G., J. E. Karp, D. Schron, and R. Saral. 1986. Increased incidence of fungemia caused by Candida krusei. J. Clin. Microbiol.24:581-584.
  • 161. Messer, S. A., D. J. Diekema, L. Boyken, S. Tendolkar, R. J. Hollis, and M. A. Pfaller. 2006. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol.44:324-326.
  • 162. Meyer, M. H., V. Letscher-Bru, B. Jaulhac, J. Waller, and E. Candolfi. 2004. Comparison of Mycosis IC/F and Plus Aerobic/F media for diagnosis of fungemia by the Bactec 9240 system. J. Clin. Microbiol.42:773-777.
  • 163. Miller, L. G., R. A. Hajjeh, and J. E. Edwards, Jr. 2001. Estimating the cost of nosocomial candidemia in the United States. Clin. Infect. Dis.32:1110. [[PubMed]
  • 164. Miller, N. S., J. D. Dick, and W. G. Merz. 2006. Phenotypic switching in Candida lusitaniae on copper sulfate indicator agar: association with amphotericin B resistance and filamentation. J. Clin. Microbiol.44:1536-1539.
  • 165. Minari, A., R. Hachem, and I. Raad. 2001. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin. Infect. Dis.32:186-190. [[PubMed]
  • 166. Mondal, R. K., S. C. Singhi, A. Chakrabarti, and M. Jayashree. 2004. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr. Crit. Care Med.5:561-565. [[PubMed]
  • 167. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347:2020-2029. [[PubMed]
  • 168. Morgan, J., M. I. Meltzer, B. D. Plikaytis, A. N. Sofair, S. Huie-White, S. Wilcox, L. H. Harrison, E. C. Seaberg, R. A. Hajjeh, and S. M. Teutsch. 2005. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol.26:540-547. [[PubMed]
  • 169. Morgan, J., K. A. Wannemuehler, K. A. Marr, S. Hadley, D. P. Kontoyiannis, T. J. Walsh, S. K. Fridkin, P. G. Pappas, and D. W. Warnock. 2005. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol.43(Suppl. I):S49-S58. [[PubMed]
  • 170. Morrell, M., V. J. Fraser, and M. J. Kollef. 2005. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother.49:3640-3645.
  • 171. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother.49:767-769.
  • 172. Munoz, P., A. Burillo, and E. Bouza. 2000. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int. J. Antimicrob. Agents15:83-90. [[PubMed]
  • 173. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 2nd ed., M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 174. National Committee for Clinical Laboratory Standards. 2004. Methods for antifungal disk diffusion susceptibility testing of yeasts: approved guideline, M44-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 175. Nevado, J., A. De Alarcon, and A. Hernandez. 2005. Caspofungin: a new therapeutic option for fungal endocarditis. Clin. Microbiol. Infect.11:248. [[PubMed]
  • 176. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. V. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis.177:425-430. [[PubMed]
  • 177. Nho, S., M. J. Anderson, C. B. Moore, and D. W. Denning. 1997. Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J. Clin. Microbiol.35:1036-1039.
  • 178. Niimi, K., K. Maki, F. Ikeda, A. R. Holmes, E. Lamping, M. Niimi, B. C. Monk, and R. D. Cannon. 2006. Overexpresison of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob. Agents Chemother.50:1148-1155.
  • 179. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother.44:196-199.
  • 180. Nucci, M., and K. A. Marr. 2005. Emerging fungal diseases. Clin. Infect. Dis.41:521-526. [[PubMed]
  • 181. O'Day, D. M., W. A. Ray, R. D. Robinson, and W. S. Head. 1987. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin. Investig. Ophthalmol. Vis. Sci.29:596-603. [[PubMed]
  • 182. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Governado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriquez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol.42:3475-3482.
  • 183. Offit, P. A., and G. Peter. 2003. The meningococcal vaccine—public policy and individual choices. N. Engl. J. Med.349:2353-2356. [[PubMed]
  • 184. O'Grady, N. P., M. Alexander, E. P. Dellinger, J. L. Gerberding, S. O. Heard, D. G. Maki, H. Masur, R. P. McCormick, L. A. Mermal, M. L. Pearson, I. I. Raad, A. Randolph, and R. A. Weinstein. 2002. Guidelines for the prevention of intravascular catheter-related infections. Morb. Mortal. Wkly. Rep.51:1-29. [[PubMed]
  • 185. Ostrosky-Zeichner, L. 2003. New approaches to the risk of Candida in the intensive care unit. Curr. Opin. Infect. Dis.16:533-537. [[PubMed]
  • 186. Ostrosky-Zeichner, L. 2004. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis.23:739-744. [[PubMed]
  • 187. Ostrosky-Zeichner, L., A. M. L. Oude Lashof, B. J. Kullberg, and J. H. Rex. 2003. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis.22:651-655. [[PubMed]
  • 188. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother.47:3149-3154.
  • 189. Ostrosky-Zeichner, L., D. Kontoyiannis, J. Raffalii, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. J. van Rensburg, J. H. Rex, W. Lau, D. Facklam, and D. N. Buell. 2005. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis.24:654-661. [[PubMed]
  • 190. Ostrosky-Zeichner, L., and P. G. Pappas. 2006. Invasive candidiasis in the intensive care unit. Crit. Care Med.34:857-863. [[PubMed]
  • 191. Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol.44:1740-1743.
  • 192. Paphitou, N. I., L. Ostrosky-Zeichner, and J. H. Rex. 2005. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med. Mycol.43:235-243. [[PubMed]
  • 193. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, and W. E. Dismukes. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis.37:634-643. [[PubMed]
  • 194. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards for the Infectious Diseases Society of America. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis.38:161-189. [[PubMed]
  • 195. Parizkova, R., V. Cerny, and P. Dostal. 2000. The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziol. Neodkladna Pece.11:271-275. [PubMed]
  • 196. Park, B. J., B. A. Arthington-Skaggs, R. A. Hajjeh, N. Iqbal, M. A. Ciblak, W. Lee-Yang, M. D. Hariston, M. Phelan, B. D. Plikaytis, A. N. Sofair, L. H. Harrison, S. K. Fridkin, and D. W. Warnock. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother.50:1287-1292.
  • 197. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother.49:3264-3273.
  • 198. Pastor, P., F. B. Medley, and T. V. Murphy. 2000. Meningococcal disease in Dallas County, Texas: results of a six-year population-based study. Pediatr. Infect. Dis.19:324-328. [[PubMed]
  • 199. Patterson, T. F., W. R. Kirkpatrick, M. White, J. W. Hiemenz, J. R. Wingard, B. Dupont, M. G. Rinaldi, D. A. Stevens, and J. R. Graybill. 2000. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore)79:250-260. [[PubMed]
  • 200. Pelz, R. K., P. A. Lipset, S. M. Swoboda, M. Diener-West, N. R. Power, R. G. Brower, T. M. Perl, J. M. Hammond, and C. W. Hendrix. 2000. Candida infections: outcome and attributable ICU costs in critically ill patients. J. Intensive Care Med.15:255-261. [PubMed]
  • 201. Pelz, R. K., C. W. Hendrix, S. M. Swoboda, M. Diener-West, W. G. Merz, J. Hammond, and P. A. Lipsett. 2001. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg.233:542-548.
  • 202. Peyron, F., A. Favel, A. Michel-Nguyen, M. Gilly, P. Regli, and A. Bolmstrom. 2001. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J. Clin. Microbiol.39:339-342.
  • 203. Pfaller, M., I. Cabezudo, F. Koontz, M. Bale, and R. Gingrich. 1987. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur. J. Clin. Microbiol.6:628-633. [[PubMed]
  • 204. Pfaller, MA. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis.22(Suppl. 2):S89-S94. [[PubMed][Google Scholar]
  • 205. Pfaller, MA. 1998. The epidemiology of invasive mycoses—narrowing the gap. Clin. Infect. Dis.27:1148-1150. [[PubMed][Google Scholar]
  • 206. Pfaller, MA. 2004. Anidulafungin: an echinocandin antifungal. Expert Opin. Investig. Drugs13:1183-1197. [[PubMed][Google Scholar]
  • 207. Pfaller, MA. 2005. Antifungal susceptibility testing methods. Curr. Drug Targets6:929-943. [[PubMed][Google Scholar]
  • 208. Pfaller, M. A., S. A. Messer, and R. J. Hollis. 1994. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Microbiol. Infect. Dis.20:127-133. [[PubMed]
  • 209. Pfaller, M. A., S. A. Messer, and A. Bolmstrom. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis.32:223-227. [[PubMed]
  • 210. Pfaller, M. A., and D. J. Diekema. 2002. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol.40:3551-3557.
  • 211. Pfaller, M. A., S. A. Messer, L. Boyken, H. Huynh, R. J. Hollis, and D. J. Diekema. 2002. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother.46:3518-3521.
  • 212. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother.46:1723-1727.
  • 213. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, R. J. Hollis, and the SENTRY Participants Group. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol.40:852-856.
  • 214. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2003. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol.41:2176-2179.
  • 215. Pfaller, M. A., and R. P. Wenzel. 2003. The epidemiology of fungal infections, p. 3-19. In E. J. Anaissie, M. R. McGinnis, and M. A. Pfaller (ed.), Clinical mycology. Churchill Livingstone, Philadelphia, PA.
  • 216. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol.42:4419-4431.
  • 217. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect.10(Suppl. 1):11-23. [[PubMed]
  • 218. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol.42:3117-3119.
  • 219. Pfaller, M. A., K. C. Hazen, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol.42:3607-3612.
  • 220. Pfaller, M. A., L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J. Clin. Microbiol.42:4977-4979.
  • 221. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J. Clin. Microbiol.42:3142-3146.
  • 222. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn. Microbiol. Infect. Dis.48:201-205. [[PubMed]
  • 223. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol.43:3807-3810.
  • 224. Pfaller, M. A., D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and B. P. Goldstein. 2005. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother.49:4795-4797.
  • 225. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol.43:5425-5427.
  • 226. Pfaller, M. A., D. J. Diekema, M. G. Rinaldi, R. Barnes, B. Hu, A. V. Veselov, N. Tiraboschi, E. Nagy, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2005. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol.43:5848-5859.
  • 227. Pfaller, M. A., L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2005. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol.43:5208-5213.
  • 228. Pfaller, M. A., and R. N. Jones for the Microbiology Resource Committee of the College of American Pathologists. 2006. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists (CAP) Microbiology Surveys Program (2001-2003). Arch. Pathol. Lab. Med.130:767-778. [[PubMed]
  • 229. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol.44:760-763.
  • 230. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol.44:819-826.
  • 231. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev.19:435-447.
  • 232. Pfaller, M. A., P. G. Pappas, and J. R. Wingard. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis.43:S3-S14. [PubMed]
  • 233. Pfaller, M. A., D. J. Diekema, M. Mendez, C. Kibbler, P. Erzebert, S. C. Chang, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group. 2006. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol.44:3551-3556.
  • 234. Pfaller, M. A., D. J. Diekema, A. L. Colombo, C. Kibbler, K. Peng, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group. 2006. Candida rugosa, an emerging pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol.44:3578-3582.
  • 235. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol.44:3533-3538.
  • 236. Piarroux, R., F. Grenouillet, P. Balvay, V. Tran, G. Blasoc, L. Millon, and A. Boillot. 2004. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit. Care Med.32:2443-2449. [[PubMed]
  • 237. Pittet, D., M. Monod, P. M. Suter, E. Frenck, and R. Auckenthaler. 1994. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg.220:751-758.
  • 238. Playford, E. G., A. C. Webster, T. C. Sorrell, and J. C. Craig. 2006. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J. Antimicrob. Chemother.57:628-638. [[PubMed]
  • 239. Poikonen, E., O. Lyytikaninen, V. J. Anttila, and P. Ruutu. 2003. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis.9:985-990.
  • 240. Prentice, H. G., C. C. Kibbler, and A. G. Prentice. 2000. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br. J. Haematol.110:273-284. [[PubMed]
  • 241. Pujol, C., M. Pfaller, and D. R. Soll. 2002. Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J. Clin. Microbiol.40:2729-2740.
  • 242. Pujol, C., M. A. Pfaller, and D. R. Soll. 2004. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob. Agents Chemother.48:262-266.
  • 243. Puzniak, L., S. Teutsch, W. Powderly, and L. Polish. 2004. Has the epidemiology of nosocomial candidemia changed? Infect. Control Hosp. Epidemiol.25:628-633. [[PubMed]
  • 244. Redding, S. W., W. R. Kirkpatrick, B. J. Coco, L. Sadkowski, A. W. Fothergill, M. G. Rinaldi, T. Y. Eng, and T. F. Patterson. 2002. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J. Clin. Microbiol.40:1879-1881.
  • 245. Redding, S. W., W. R. Kirkpatrick, S. Saville, B. J. Coco, W. White, A. Fothergill, M. Rinaldi, T. Eng. T. F. Patterson, and J. Lopez-Ribot. 2003. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol.41:619-622.
  • 246. Redding, S. W., K. A. Marr, W. R. Kirkpatrick, B. J. Coco, and T. F. Patterson. 2004. Candida glabrata sepsis secondary to oral colonization in bone marrow transplantation. Med. Mycol.42:479-481. [[PubMed]
  • 247. Rees, J. R., R. W. Pinner, R. A. Hajjeh, M. E. Brandt, and A. L. Reingold. 1998. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: results of a population-based laboratory active surveillance. Clin. Infect. Dis.27:1138-1147. [[PubMed]
  • 248. Reingold, A. L., X. D. Lu, B. D. Plikaytis, and L. Ajello. 1986. Systemic mycoses in the United States, 1980-1982. J. Med. Vet. Mycol.24:433-436. [[PubMed]
  • 249. Reinhardt, J. F., P. J. Ruane, L. J. Walker, and W. L. George. 1985. Intravenous catheter-associated fungemia due to Candida rugosa. J. Clin. Microbiol.22:1056-1057.
  • 250. Rello, J. 1999. Impact of nosocomial infections on outcome: myths and evidence. Infect. Control Hosp. Epidemiol.20:392-394. [[PubMed]
  • 251. Rentz, A. M., M. T. Halpern, and R. Bowden. 1998. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis.27:781-788. [[PubMed]
  • 252. Rex, JH. 2006. Antifungal prophylaxis in the intensive care unit: who should get it? Crit. Care Med.34:1286-1287. [[PubMed][Google Scholar]
  • 253. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. O. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med.331:1325-1330. [[PubMed]
  • 254. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother.39:906-909.
  • 255. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis.24:235-247. [[PubMed]
  • 256. Rex, J. H., M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, and D. W. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev.14:643-658.
  • 257. Rex, J. H., and J. D. Sobel. 2001. Prophylactic antifungal therapy in the intensive care unit. Clin. Infect. Dis.32:1191-1200. [[PubMed]
  • 258. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis.35:982-989. [[PubMed]
  • 259. Richet, H., P. Roux, C. Des Champs, Y. Esnault, A. Andremont, and the French Candidemia Study Group. 2002. Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect.8:405-412. [[PubMed]
  • 260. Saiman, L., E. Ludington, M. Pfaller, S. Rangel-Frausto, R. T. Wiblin, J. Dawson, H. M. Blumberg, J. E. Patterson, M. Rinaldi, J. E. Edwards, R. P. Wenzel, and W. Jarvis. 2000. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr. Infect. Dis. J.19:319-324. [[PubMed]
  • 261. Sandford, G. R., W. G. Merz, J. R. Wingard, P. Charache, and R. Saral. 1980. The value of fungal surveillance cultures as predictors of systemic fungal infections. J. Infect. Dis.142:503-509. [[PubMed]
  • 262. Sandven, P., K. Nilsen, A. Digranes, T. Tjade, and J. Lassen. 1997. Candida norvegenesis: a fluconazole-resistant species. Antimicrob. Agents Chemother.41:1375-1376.
  • 263. Sandven, P., H. Qvist, E. Skovlund, K. E. Gierksky, the NORGAS Group, and the Norwegian Yeast Study Group. 2002. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit. Care Med.30:541-547. [[PubMed]
  • 264. Sandven, P., L. Bevanager, A. Digranes, H. H. Haukland, T. Mannsaker, P. Gausted, and the Norwegian Yeast Study Group. 2006. Candidemia in Norway, 1991 to 2003: results from a nationwide study. J. Clin. Microbiol.44:1977-1981.
  • 265. Sanguinetti, M., B. Posteraro, B. Fiori, S. Ranno, R. Torelli, and G. Fadda. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother.49:668-679.
  • 266. Sarria, J. C., J. C. Bradley, R. Habash, K. T. Mitchell, R. C. Kimbrough, and A. M. Vidal. 2005. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin. Infect. Dis.40:e46-e48. [[PubMed]
  • 267. Sarvikivi, E., O. Lyytikainen, D. R. Soll, C. Pujol, M. A. Pfaller, M. Richardson, P. Koukila-Kahkola, P. Luukkainern, and H. Saxen. 2005. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol.43:2729-2735.
  • 268. Savino, J. A., N. Agarival, P. Wry, A. Policastro, T. Cerabona, and L. Austria. 1994. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J. Trauma36:20-25. [[PubMed]
  • 269. Saxen, H., M. Virtanen, P. Carlson, K. Hoppa, M. Pohjavuori, M. Vaara, J. Vuopio-Varkila, and H. Peltola. 1995. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr. Infect. Dis. J.14:776-781. [[PubMed]
  • 270. Scholer, HJ. 1980. Flucytosine, p. 35-106. In D. C. E. Speller (ed.), Antifungal chemotherapy. John Wiley & Sons, Ltd., Chichester, United Kingdom.[Google Scholar]
  • 271. Segal, B. H., J. Kwon-Chung, T. J. Walsh, B. S. Klein, M. Batiwalla, N. G. Almyroudi, S. M. Holland, and L. Romani. 2006. Immunotherapy for fungal infections. Clin. Infect. Dis.42:507-515. [[PubMed]
  • 272. Sharpe, M. D., C. Ghent, D. Grant, G. L. Hornby, J. McDougal, and W. David Colby. 2003. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation76:977-983. [[PubMed]
  • 273. Sheng, W. H., J. T. Wang, D. C. T. Lu, W. C. Chie, Y. C. Chen, and S. C. Chang. 2005. Comparative impact of hospital-acquired infections on medical costs, length of hospital stay and outcome between community hospitals and medical centers. J. Hosp. Infect.59:205-214. [[PubMed]
  • 274. Shin, J. H., S. J. Kee, M. G. Shin, S. H. Kim, D. H. Shin, S. K. Lee, S. P. Suh, and D. W. Ryang. 2002. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J. Clin. Microbiol.40:1244-1248.
  • 275. Shorr, A. F., K. Chung, W. L. Jackson, P. E. Waterman, and M. H. Kollef. 2005. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit. Care Med.33:1928-1935. [[PubMed]
  • 276. Siwek, G. T., M. A. Pfaller, P. M. Polgreen, S. Cobb, P. Hoth, M. Magalheas-Silverman, and D. J. Diekema. 2006. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn. Microbiol. Infect. Dis.55:209-212. [[PubMed]
  • 277. Slotman, G. J., and K. W. Burchard. 1987. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch. Surg.122:147-151. [[PubMed]
  • 278. Sobel, J. D., and J. H. Rex. 2001. Invasive candidiasis: turning risk into a practical prevention policy. Clin. Infect. Dis.33:187-190. [[PubMed]
  • 279. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis.42:244-251. [[PubMed]
  • 280. Steinbach, W. J., and D. A. Stevens. 2003. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis.37(Suppl. 3):S157-S187. [[PubMed]
  • 281. Steinbach, W. J., D. A. Stevens, and D. W. Denning. 2003. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis.37(Suppl. 3):S188-S224. [[PubMed]
  • 282. Sterling, T., and W. G. Merz. 1998. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist. Updates1:161-165. [[PubMed]
  • 283. Sterling, T. R., R. A. Gasser, and A. Ziegler. 1996. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin. Infect. Dis.23:187-188. [[PubMed]
  • 284. St. Germain, G., M. Laverdieu, R. Pelletier, A. M. Bourgault, M. Libman, C. Lemieux, and G. Noel. 2001. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results from a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol.39:949-953.
  • 285. Stiller, R. L., J. E. Bennett, H. J. Scholer, M. Wall, A. Polak, and D. A. Stevens. 1982. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob. Agents Chemother.22:482-487.
  • 286. Stiller, R. L., J. E. Bennett, H. J. Scholer, M. Wall, A. Polak, and D. A. Stevens. 1983. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J. Infect. Dis.147:1070-1077. [[PubMed]
  • 287. Strausbaugh, L. J., D. L. Sewell, T. T. Ward, M. A. Pfaller, T. Heitzman, and R. Tjoelker. 1994. High frequency of yeast carriage on hands of hospital personnel. J. Clin. Microbiol.32:2299-2300.
  • 288. Sugar, A. M., and D. A. Stevens. 1985. Candida rugosa in immunocompromised infection. Case report, drug susceptibility, and a review of the literature. Cancer56:318-320. [[PubMed]
  • 289. Sugita, T., K. Takeo, M. Ohkusu, E. Virtudazo, M. Takashima, E. Asako, F. Ohshima, S. Harada, C. Yanaka, A. Nishikawa, L. Majoros, and M. Sipiczki. 2004. Fluconazole-resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production. Microbiol. Immunol.48:761-766. [[PubMed]
  • 290. Tassel, D., and M. A. Madoff. 1968. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine, a new antifungal agent. JAMA206:830-832. [[PubMed]
  • 291. Tietz, H. J., V. Czaika, and W. Sterry. 1999. Case report: osteomyelitis caused by highly-resistant Candida guilliermondii. Mycoses42:577-580. [[PubMed]
  • 292. To, W. K., A. W. Fothergill, and M. G. Rinaldi. 1995. Comparative evalution of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J. Clin. Microbiol.33:2660-2664.
  • 293. Torfs, K. 1997. Economic aspects of treatment for fungal infections in cancer patients. Eur. J. Clin. Microbiol. Infect. Dis.16:98-107. [[PubMed]
  • 294. Tortorano, A. M., E. Biraghi, A. Astofi, C. Ossi, M. Tejada, C. Farina, S. Perin, C. Bonacccorso, C. Cavanna, A. Raballo, A. Grossi, and the FIMUA Candidemia Study Group. 2002. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J. Hosp. Infect.51:297-304. [[PubMed]
  • 295. Tortorano, A. M., A. L. Rigoni, E. Biraghi, A. Prigatino, M. A. Viviani, and the FIMUA-FCMM Candidemia Study Group. 2003. The European Confederation of Medical Mycology (ECMM) survey of candidemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J. Antimicrob. Chemother.52:679-682. [[PubMed]
  • 296. Tortorano, A. M., J. Peman, H. Bernhardt, L. Klingspor, C. C. Kibbler, O. Faure, E. Birahi, E. Canton, K. Zimmermann, S. Seaton, R. Grillot, and the ECMM Working Group on Candidaemia. 2004. Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis.23:317-322. [[PubMed]
  • 297. Trick, W. E., S. K. Fridkin, J. R. Edwards, R. A. Hajjeh, R. P. Gaynes, and the National Nosocomial Infections Surveillance System Hospitals. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis.35:622-630. [[PubMed]
  • 298. Uzun, O., and E. J. Anaissie. 1996. Problems and controversies in the management of hematogenous candidiasis. Clin. Infect. Dis.22:953-1015. [[PubMed]
  • 299. Vandeputte, P., G. Larcher, T. Berges, G. Renier, D. Chabasse, and J. P. Bourchara. 2005. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob. Agents Chemother.49:4608-4615.
  • 300. Vardakas, K. Z., G. Samonis, A. Michalopoulos, E. S. Soteriades, and M. E. Falgas. 2006. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit. Care Med.34:1216-1224. [[PubMed]
  • 301. Vazquez, JA. 2005. Anidulafungin: a new echinocandin with a novel profile. Clin. Ther.27:657-673. [[PubMed][Google Scholar]
  • 302. Vazquez, J. A., A. Chen, M. Buhari, J. Chandra, P. Mukhejie, and M. A. Ghannoum. 2006. Abstr. 8th ASM Conf. Candida Candidiasis, abstr. A67.
  • 303. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity, and drug interactions. J. Antimicrob. Chemother.46:171-179. [[PubMed]
  • 304. Vincent, J. L., E. Anaissie, H. Bruining, W. Demajo, M. el-Ebiary, J. Haber, Y. Hiramatsu, G. Nitenberg, P. O. Nystrom, D. Pittet, T. Rogers, P. Sandven, G. Sganga, M. D. Schaller, and J. Solomkin. 1998. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med.34:206-216. [[PubMed]
  • 305. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, B. De Pauw, F. Meunier, and the Invasive Fungal Infection Group of the EORTC. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organizaiton for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis.28:1071-1079. [[PubMed]
  • 306. Waggoner-Fountain, L. A., M. W. Walker, R. J. Hollis, M. A. Pfaller, J. E. Ferguson II, R. P. Wenzel, and L. G. Donowitz. 1996. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin. Infect. Dis.22:803-808. [[PubMed]
  • 307. Walsh, T. J., and W. G. Merz. 1986. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am. J. Clin. Pathol.85:498-502. [[PubMed]
  • 308. Walsh, T. J., A. Groll, J. Hiemenz, R. Flemming, E. Roilides, and E. Anaissie. 2004. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect.10(Suppl. 1):48-66. [[PubMed]
  • 309. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother.39:2520-2522.
  • 310. Weems, JJ., Jr. 1992. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin. Infect. Dis.14:756-766. [[PubMed][Google Scholar]
  • 311. Wenzel, RP. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis.20:1531-1534. [[PubMed][Google Scholar]
  • 312. Wenzel, R. P., and M. A. Pfaller. 1991. Candida species: emerging hospital bloodstream pathogens. Infect. Control Hosp. Epidemiol.12:523-524. [[PubMed]
  • 313. Wenzel, R. P., and M. B. Edmonds. 2001. The impact of hospital-acquired bloodstream infections. Emerg. Infect. Dis.7:174-177.
  • 314. Wenzel, R. P., and C. Gennings. 2005. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin. Infect. Dis.41(Suppl. 6):S389-S393. [[PubMed]
  • 315. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med.148:2642-2645. [[PubMed]
  • 316. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1989. Risk factors for hospital-acquired candidemia. Arch. Intern. Med.149:2349-2353. [[PubMed]
  • 317. White, M. 1997. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin. Infect. Dis.24:1129-1130. [[PubMed]
  • 318. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev.11:382-402.
  • 319. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum, and clinical efficacy. Expert Opin. Investig. Drugs12:1313-1333. [[PubMed]
  • 320. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis.190:1464-1471. [[PubMed]
  • 321. Wilson, L. S., C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. 2002. The direct cost and incidence of systemic fungal infections. Value Health5:26-34. [[PubMed]
  • 322. Wingard, JR. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis.20:115-125. [[PubMed][Google Scholar]
  • 323. Wingard, J. R., J. D. Dick, W. G. Merz, G. R. Sanford, R. Saral, and W. H. Burns. 1982. Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infect. Immun.37:833-836.
  • 324. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med.325:1274-1277. [[PubMed]
  • 325. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother.37:1847-1849.
  • 326. Winston, D. J., A. Pakrasi, and R. W. Busuttil. 1999. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.131:729-737. [[PubMed]
  • 327. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis.39:309-317. [[PubMed]
  • 328. Yamamura, D. L. R., C. Rotstein, L. E. Nicolle, S. Ioannou, and the Fungal Disease Registry of the Canadian Infectious Disease Society. 1999. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. CMAJ160:493-499.
  • 329. Yang, Y. L., S. Y. Li, H. H. Chang, and H. J. Lo. 2005. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn. Microbiol. Infect. Dis.51:179-183. [[PubMed]
  • 330. Yoon, S. A., J. A. Vazquez, P. E. Stefan, J. D. Sobel, and R. A. Akins. 1999. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob. Agents Chemother.43:836-845.
  • 331. Yu, M., and GTomasa. 1993. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med.21:1635-1642. [[PubMed][Google Scholar]
  • 332. Zaas, A. K., and B. D. Alexander. 2005. Echinocandins: role in antifungal therapy, 2005. Expert Opin. Pharmacother.6:1657-1668. [[PubMed]
  • 333. Zaoutis, T. E., J. Argon, J. Chu, J. A. Berlin, T. J. Walsh, and C. Feudtner. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis.41:1232-1239. [[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.